Acquiring Company
Gilead Sciences
Acquired Company
Ouro Medicines
Foster CitySan FranciscoBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Gilead Sciences is approaching a $2 billion acquisition of Ouro Medicines, a biotech specializing in immune disorder treatments. The deal includes an upfront payment of approximately $1.5 billion and additional funds tied to clinical trial milestones. An announcement regarding the acquisition is expected soon, although terms may vary.
Quick answer
Gilead Sciences is acquiring Ouro Medicines for $2 billion, announced March 23, 2026. Gilead Sciences is based in Foster City, California, United States.
- How much did Gilead Sciences pay for Ouro Medicines?
- The reported deal value is $2 billion.
- What does Gilead Sciences do?
- Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
- Where are Gilead Sciences and Ouro Medicines based?
- Gilead Sciences is based in Foster City, California, United States. Ouro Medicines is based in San Francisco, California, United States.
- Who are the decision-makers at Gilead Sciences?
- Fundz holds 1 contact at Gilead Sciences. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Therapeutics and Biopharma
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Aurinia acquires Kezar Life Sciences for $6.955/share (March 30, 2026)
- ESTEVE acquires TerSera's Infusion Business Unit (May 4, 2026)
- Eli Lilly to acquire Ajax Therapeutics for $2.3B, $2.3B (April 27, 2026)
- Lilly to acquire Ajax Therapeutics for patient care (April 27, 2026)
- Sanofi completes acquisition of Dynavax Technologies (April 23, 2026)
- Lilly to acquire Centessa for $38/share (April 17, 2026)
Who to call at Gilead Sciences, and when
When Gilead Sciences changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Gilead Sciences raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Gilead Sciences, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Gilead Sciences. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Gilead Sciences makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Ouro Medicines?
Ouro Medicines was acquired by Gilead Sciences, based in Foster City. The deal was reported on March 23, 2026. Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. Gilead Sciences is publicly traded (GILD) and operates in Biotechnology.
When did Gilead Sciences acquire Ouro Medicines?
Gilead Sciences's acquisition of Ouro Medicines was reported on March 23, 2026. Gilead Sciences is approaching a $2 billion acquisition of Ouro Medicines, a biotech specializing in immune disorder treatments. The deal includes an upfront payment of approximately $1.5 billion and additional funds tied to clinical trial milestones. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Ouro Medicines do?
Ouro Medicines is a biotechnology company focused on developing immune reset therapeutics for chronic immune-mediated diseases. It is privately held, operating in Biotechnology, and is based in San Francisco.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.